Biased research, aggressive sales, harmful drugs
The Health Policy Exchange
MAY 20, 2013
Unfortunately, recent case studies have illustrated that FDA approval does not necessarily provide assurances of effectiveness and safety. Very quickly, the market included nearly all dialysis patients, not just the roughly 16 percent who required blood transfusions. The size of average doses would more than triple.
Let's personalize your content